SHILPA MEDICARE LTD. - 530549 - Clarification sought from Shilpa Medicare Ltd
The Exchange has sought clarification from Shilpa Medicare Ltd on March 10, 2023, with reference to Movement in Volume.The reply is awaited.10-03-2023
10-03-2023
Shilpa Medicare over two-week high with single day rally, Rs 305-310 crucial for getting into momentum
On Thursday, Shilpa Medicare recouped most of those losses and has formed long bullish candlestick pattern on the daily charts with significantly higher volumes, after forming Doji kind of pattern in previous session. It was the second biggest gainer in the Nifty500 index.10-03-2023
Shilpa Medicare back in action, tops Nifty500 list with over 9% gains
After a 24 percent rally in two back-to-back sessions, the stock retreated to close 8 percent lower on February 20 but recouped the day's losses with a massive rally today21-02-2023
SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
In furtherance to our intimation dated 13th February 2023 & 16th February 2023 with regard to the Q3 FY23 Conference Call held on Wednesday, 15th February 2023 at 04.00 PM IST, please find the enclosed transcript of the call.21-02-2023
Shilpa Medicare continues to rally for second day, settles over 15% higher
The stock on February 15 hit the lowest level since September 4, 2019.17-02-2023
SHILPA MEDICARE LTD. - 530549 - Shilpa Medicare Limited, Unit VI, Bengaluru Facility Has Successfully Registered With Ministry Of Health, United Arab Emirates
This is to inform you that the Company's Bengaluru facility for manufacture and testing of Orodispersible films and Transdermal systems has been successfully registered with Ministry of Health, United Arab Emirates. This registration enables company to register the products (Orodispersible films and Transdermal systems) in UAE for commercialization. The facility is involved in manufacturing and testing of specialized dosage forms eg. Orodispersible Films and Transdermal systems. The facility is backed up with strong Research and Development of Orodispersible films and transdermal technologies. The GMP facility is equipped with state of art machinery for the needs of Global commercial requirements. The facility has already been issued GMP by UK MHRA. The facility also manufactures dietary supplements in orodispersible films and was registered with US FDA Food Facility registry. The facility is actively exporting dietary supplements to US Market.16-02-2023
SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to our letter dated 13th February 2023, please note that the audio recording of the conference call for Investors/Analysts for the discussion on Q3 FY23 results, held on 15th February 2023, at 04.00p.m.(IST), has been uploaded on our website.16-02-2023
SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication of Un-audited Standalone and Consolidated Financial Results for the Quarter ended 31 December, 202215-02-2023
SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Investor Presentation
With reference to the captioned subject, the Investor Presentation of the Company for the Quarter ended 31 December 2022 with regard to Business highlights, financial performance and other updates is attached herewith for your consideration.15-02-2023
SHILPA MEDICARE LTD. - 530549 - Board Meeting Outcome for Outcome Of Board Meeting
With reference to the subject cited above, this is to intimate that the Board of Directors in its meeting held on 14 February 2023 which commenced at 02.00 p.m. and concluded at 04:03p.m. have inter alia considered and approved Un-Audited Financial Results (Standalone and Consolidated) for the quarter ended 31 December 2022. A copy of Limited Review Report is also enclosed as Annexure 1.14-02-2023